NCT06976619RecruitingPhase 2
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 5 May 2025
- Start date
- 3 Oct 2025
- Primary completion date
- 30 Oct 2028
- Lead sponsor
- Mayo Clinic
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT06976619
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 3 Oct 2025 to the primary completion date, 30 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Prior use of GLP-1 receptor agonists in the previous year.
Other illness
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Lab values
- HbA1c \> 10.0%
Age
- Age \< 25 or \> 70 years.
Other
- For female subjects: positive pregnancy test at the time of enrollment or study
Who the study is looking for
- Type 1 or type 2 diabetes treated with insulin
Age in the registry: 25 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.